BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korea's LOTTE Biologics secures major commercial manufacturing agreement ahead of Songdo Plant 1 launch

November 18, 2026 | News

Establishes a commercial manufacturing partnership upon completion of the plant, with full-scale commercial production to begin in 2027



South Korea-based LOTTE Biologics has announced a major commercial manufacturing agreement with a global pharmaceutical company, marking a significant milestone in the commercialisation of its Songdo Bio Campus.

The agreement represents the first major commercial manufacturing commitment for Songdo Plant 1, secured ahead of its operational launch. Under the partnership, LOTTE Biologics will provide integrated drug substance and drug product manufacturing services for key products in the customer's portfolio, with commercial production targeted to begin in 2027.

Securing commercial manufacturing volume while the facility is still under development underscores customer confidence in LOTTE Biologics' technical expertise, execution capabilities, and long-term supply reliability.

Designed to meet the evolving demands of global biopharmaceutical manufacturing, Songdo Plant 1 features state-of-the-art production infrastructure, advanced automation, and large-scale cold-chain warehousing to support efficient, reliable, and quality-driven operations.

The Songdo Bio Campus is being developed with a planned capacity of 360,000 liters across three plants, with Plant 1 providing 120,000 liters through eight 15,000-liter stainless-steel bioreactors.

The facility will complement LOTTE Biologics' established Syracuse Bio Campus in New York, which brings more than two decades of manufacturing experience, a track record supporting over 62 regulatory approvals, and a recent FDA inspection completed with zero observations.